CSIMarket
 


Moonlake Immunotherapeutics  (MLTX)
Other Ticker:  
 

Cumulative Moonlake Immunotherapeutics's Leverage Ratio for Trailing Twelve Months Period

MLTX's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

MLTX Leverage Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth 646.71 % 493.02 % 427.83 % 142.31 % -
Y / Y Total Liabilities Growth 1.97 % 133.42 % -50.86 % 147.73 % -77.37 %
Leverage Ratio for Trailing Twelve Months Period 0.09 0.13 0.14 0.39 0.39
Total Ranking # 15 # 28 # 42 # 163 # 1922
Seq. Equity Growth 4.87 % -1.9 % 744.34 % -14.04 % -16.72 %
Seq. Total Liabilities Growth -62.32 % 348.82 % -32.12 % -11.18 % -13.74 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to debt repayement of -62.32% Moonlake Immunotherapeutics decreased Leverage Ratio for Trailing Twelve Months Period in the IV. Quarter to 0.09, below company's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 8 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Moonlake Immunotherapeutics. While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are MLTX's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 9
Sector # 12
S&P 500 # 38


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
32.13 5.07 0.02
(Mar 31 2022)   (Dec 31 2023)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage Ratio for Trailing Twelve Months Period
Immunic Inc   0.25 
Dyne Therapeutics Inc   0.24 
Taro Pharmaceutical Industries Ltd  0.23 
Erasca Inc   0.23 
Deciphera Pharmaceuticals Inc   0.23 
Xilio Therapeutics inc   0.23 
Regeneron Pharmaceuticals Inc   0.23 
Galmed Pharmaceuticals Ltd   0.23 
Xencor Inc  0.23 
Renovaro Inc   0.23 
Pepgen Inc   0.23 
Lianbio  0.23 
Affimed N v   0.23 
Genprex Inc   0.23 
Ligand Pharmaceuticals Incorporated  0.23 
Lipella Pharmaceuticals Inc   0.23 
Procyon Corporation  0.23 
Zynerba Pharmaceuticals Inc   0.22 
Prothena Corporation Public Limited Company  0.22 
United Therapeutics Corporation  0.22 
Tharimmune Inc   0.22 
Sanofi  0.22 
Tenax Therapeutics Inc   0.22 
Catalyst Pharmaceuticals Inc   0.22 
Assembly Biosciences Inc   0.21 
Anebulo Pharmaceuticals Inc   0.21 
Chemomab Therapeutics Ltd   0.21 
Corcept Therapeutics Inc  0.21 
Neurogene Inc   0.21 
Aldeyra Therapeutics Inc   0.21 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com